Curebase Releases New Diagnostic Offering

HeartBeam plans to initiate an Early Access Program to gather feedback from patients and physicians prior to a commercial launch.

Through AI technology, Neurophet AQUA now provides multiple sclerosis (MS) analysis with a combination of lesion quantification and enhanced segmentation of T2-FLAIR MRI.

Capital also expected to assist the advancement of Evergreen's radiopharmaceutical discovery pipeline into clinical trials.

Roche's Elecsys HBeAg quant is an immunoassay able to determine the presence and quantity of the hepatitis B e antigen in human serum and plasma.

PD-L1 IHC 22C3 pharmD approved to help identify patients who may be eligible to receive treatment with pembrolizumab (Keytruda) to treat gastric or gastroesophageal junction adenocarcinoma.

O'Neill discusses the company's place in the global market and recent advancements to improve the patient experience.